SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137
Our data demonstrate that SAIL66, designed to engage CLDN6, CD3, and CD137, has the potential to enhance antitumor activity and provide a potent therapeutic option for patients with ovarian and other solid tumors expressing CLDN6. Clinical trials are currently underway to evaluate the safety and efficacy of SAIL66.
Authors
- Hiroyuki Aburatani (ORCID: https://orcid.org/0000-0003-0438-1544)
- Tomoyuki Igawa (ORCID: https://orcid.org/0000-0003-0097-8220)
- Ryo Uchikawa
- Takehisa Kitazawa (ORCID: https://orcid.org/0000-0002-4958-7936)
- Chai Ling Pang
- Takayuki Kamikawa
- M. Shimada (ORCID: https://orcid.org/0009-0006-3726-890X)
- Junko Shinozuka (ORCID: https://orcid.org/0009-0002-3380-0760)
- Tatsushi Kodama
- Chie Kato (ORCID: https://orcid.org/0000-0001-8603-3759)
- Mika Kamata‐Sakurai (ORCID: https://orcid.org/0000-0002-7210-5544)
- Nobumoto Tomioka (ORCID: https://orcid.org/0000-0001-6751-416X)
- Sotaro Naoi
- Kenji Taniguchi (ORCID: https://orcid.org/0000-0001-5980-1943)
- Shinya Ishii (ORCID: https://orcid.org/0000-0001-5762-4066)
- Masaru Muraoka (ORCID: https://orcid.org/0000-0002-6559-9785)
- Momoko Miura-Okuda
- Shu Feng (ORCID: https://orcid.org/0000-0002-5372-4497)
- S. Akai
- Moe Yoshimoto
- N. Kimura (ORCID: https://orcid.org/0009-0003-3355-3859)
- Nishiki Nagaya
- Gupta Garvita
Institutions
- Bunkyo University (JP)
- Chugai Pharma (United States) (US)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-009563
- Citations
- 13
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.67
Funders
- University of Tokyo
- Chugai Pharmaceutical